 |
 |

The Use of Sublingual Nifedipine
A Continuing Concern
Arch Intern Med. 1999;159:2259-2260.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
IN 1995, the Cardiorenal Advisory Committee of the Food and Drug Administration, after a lengthy deliberation, unanimously decided that sublingual nifedipine should not officially be approved for the treatment of hypertensive emergencies. Despite this decision and despite authoritative voices1-4 warning against this practice, the use of short-acting nifedipine for what was perceived as hypertensive emergencies remained widespread in the United States and all over the globe.
Until recently, this intervention was used routinely in emergency departments, in nursing homes, and on hospital wards, where it often was given as a standing order, particularly in postoperative patients. In 1996, we and our colleagues5 published a review article on the putative dangers of sublingual nifedipine in hypertensive emergencies. Interestingly, short-acting nifedipine has never been approved for the treatment of any form of hypertension, emergent or not, and the safety and efficacy of this intervention remain to be determined. In view of the . . . [Full Text of this Article]
Franz H. Messerli, MD
Department of Internal Medicine Section on Hypertensive Diseases Ochsner Clinic 1514 Jefferson Hwy New Orleans, LA 70121
Ehud Grossman, MD
Tel-Hashomer, Israel
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Improved Quality of Stroke Care for Hospitalized Medicare Beneficiaries in Michigan
Jacobs et al.
Stroke 2005;36:1227-1231.
ABSTRACT
| FULL TEXT
|